Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ 136”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205 · cited 1×
“in keratinocytes to create a “danger signal” is unclear (51), but several possible molecular events may occur to activate resting dendritic APCs (52), followed by delivery of an antigenic signal”
BackgroundPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“ic inflammatory diseases, HMGB1 is also considered an important regulator (67).”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 10×
“The successful use of cyclosporin, which acts to block cytokine release, resulted in a paradigm shift away from epidermal keratinocytes to various immunocyte populations including T cell subsets and dendritic APCs.”
BackgroundInfluentialAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Cited by
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Self-citationInterleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
“Although it is still unclear how these environmental factors drive the pathogenic T cell cascade, it has been suggested that innate immune pathways may provide the missing link (6, 7).”
BackgroundSelf-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Schön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer
Karin, M., Lawrence, T., & Nizet, V. (2006) · Cell · doi:10.1016/j.cell.2006.02.016 · Cited by 942
“However, apart from NOD2, several other psoriasis susceptibility loci have been identified, and their molecular nature and relationship to innate immunity remain to be elucidated (Nickoloff and Nestle, 2004).”
BackgroundChan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060244 · Cited by 680
“No clear-cut autoantigens, however, have been described, and it is likely that the innate immune system is also involved (2).”
BackgroundPsoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins
Zenz, R., Eferl, R., Kenner, L., Florin, L., Hummerich, L., Mehic, D., Scheuch, H., Angel, P., Tschachler, E., & Wagner, E. F. (2005) · Nature · doi:10.1038/nature03963 · Cited by 599
Fos/AP‐1 proteins in bone and the immune system
Wagner, E. F., & Eferl, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00332.x · Cited by 537
“Although, at least six different psoriasis susceptibility loci, designated PSORS1-PSORS6, have been mapped using genome-wide scans, the cause of psoriasis remains largely unknown (96).”
BackgroundSa, S. M., Valdez, P. A., Wu, J., Jung, K., Zhong, F., Hall, L., Kasman, I., Winer, J., Modrusan, Z., Danilenko, D. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2229 · Cited by 514
“Analyses of infiltrates in psoriatic lesions have most consistently identified increases in myeloid-derived CD11c dendritic cells and CD4 and CD8 T cells, with plasmacytoid dendritic cells (CD11c ), monocytes/macrophages, neutrophils, and mast cells also frequently found in increased numbers (1, 2).”
BackgroundEpidermal barrier formation and recovery in skin disorders
Segre, J. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28521 · Cited by 506
Inside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462
Lowes, M. A., Chamian, F., Abello, M. V., Fuentes-Duculan, J., Lin, S.-L., Nussbaum, R., Novitskaya, I., Carbonaro, H., Cardinale, I., Kikuchi, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509736102 · Cited by 456
Community differentiation of the cutaneous microbiota in psoriasis
Alekseyenko, A. V., Perez-Perez, G. I., De Souza, A., Strober, B., Gao, Z., Bihan, M., Li, K., Methé, B. A., & Blaser, M. J. (2013) · Microbiome · doi:10.1186/2049-2618-1-31 · Cited by 441
“This observed increase in specimen heterogeneity obtained from affected individuals provides further evidence for ecosystem disruption in the clinically unaffected sites, and indicates the multiple cutaneous responses to the selectional stress introduced by the psoriatic immunopathophysiology [49-53].”
BackgroundPenna, G., Roncari, A., Amuchastegui, S., Daniel, K. C., Berti, E., Colonna, M., & Adorini, L. (2005) · Blood · doi:10.1182/blood-2005-05-2044 · Cited by 412
Capon, F., Di Meglio, P., Szaub, J., Prescott, N. J., Dunster, C., Baumber, L., Timms, K., Gutin, A., Abkevic, V., Burden, A. D., et al. (2007) · Human Genetics · doi:10.1007/s00439-007-0397-0 · Cited by 408
“Psoriasis is a chronic skin disorder, characterized by the inWltration of inXammatory eVector cells and cytokines into the dermis and the epidermis (NickoloV and Nestle 2004; Smith and Barker 2006).”
BackgroundSelf-citationAngiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383
“Together, current models suggest complex interactions between keratinocytes and cells of the immune system as initial steps in psoriasis pathogenesis (Elder et al. 1989; Christophers 1996; Nickoloff & Nestle 2004; Lowes et al. 2007; Nickoloff 2007; Rebholz et al. 2007).”
BackgroundBaliwag, J., Barnes, D. H., & Johnston, A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.014 · Cited by 373
“However, IFN-γ likely contributes to the cytokine storm in psoriasis [7] by, at the very least, aiding and abetting other cytokines, in particular, IL-17A [25,120], as well as playing a role in priming APCs [25], which drives IL-1/IL-23 production to augment Th17 responses.”
BackgroundActivator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease
Zenz, R., Eferl, R., Scheinecker, C., Redlich, K., Smolen, J., Schonthaler, H. B., Kenner, L., Tschachler, E., & Wagner, E. F. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2338 · Cited by 350
“Although at least six different psoriasis susceptibility loci (PSORS1–PSORS6) have been mapped in the human genome, the genetic basis of psoriasis remains largely unknown [42].”
Gudjonsson, J. E., & Elder, J. T. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2007.08.007 · Cited by 301
de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., & Dutz, J. P. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.2.223 · Cited by 325
“Psoriasis is a chronic inflammatory skin disease in which T-cell–mediated cytokine production drives keratinocyte proliferation and angiogenesis.(24) Although TNFis a crucial cytokine in the inflammatory cascade leadTable 3.”
BackgroundThe chemokine receptor D6 limits the inflammatory response in vivo
Jamieson, T., Cook, D. N., Nibbs, R. J. B., Rot, A., Nixon, C., Mclean, P., Alcami, A., Lira, S. A., Wiekowski, M., & Graham, G. J. (2005) · Nature Immunology · doi:10.1038/ni1182 · Cited by 302
“Many of these features are hallmarks of human psoriasis and of animal models of psoriasi”
BackgroundTillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
Wang, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27180 · Cited by 276
“Previously, introduction of an insertion mutation in the murine CD18 gene — resulting in a duplication of exons 2 and 3 — yielded a mouse model with a severe reduction of CD18 expression, at levels only 2–16% of WT (15).”
Influentialα1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis
Conrad, C., Boyman, O., Tonel, G., Tun-Kyi, A., Laggner, U., de Fougerolles, A., Kotelianski, V., Gardner, H., & Nestle, F. O. (2007) · Nature Medicine · doi:10.1038/nm1605 · Cited by 265
Self-citationOttaviani, C., Nasorri, F., Bedini, C., de Pità, O., Girolomoni, G., & Cavani, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535243 · Cited by 248
Rich, P., Sigurgeirsson, B., Thaçi, D., Ortonne, J. ‐., Paul, C. F., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12112 · Cited by 244
CCR6 is required for IL-23–induced psoriasis-like inflammation in mice
Hedrick, M. N., Lonsdorf, A. S., Shirakawa, A.-K., Lee, C.-C. R., Liao, F., Singh, S. P., Zhang, H. H., Grinberg, A., Love, P. E., Hwang, S. T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37378 · Cited by 238
Innate and adaptive immunity and the pathophysiology of psoriasis
Gaspari, A. A. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.057 · Cited by 238
Späh, F. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08780.x · Cited by 223
Gottlieb, A. B., Chao, C., & Dann, F. (2008) · Journal of Dermatological Treatment · doi:10.1080/09546630701364768 · Cited by 216
“Chronic activation of T cells ensues, resulting in a persistent cycle of inflammatory-mediated pathology and formation of the characteristic psoriatic skin lesions (1).”
Immunopathogenesis of Psoriasis
Nickoloff, B. J., Qin, J.-Z., & Nestle, F. O. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-0039-2 · Cited by 217
Self-citationComorbidities in Patients with Psoriasis
Gottlieb, A. B., & Dann, F. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.06.021 · Cited by 210
Young, C. N., Koepke, J. I., Terlecky, L. J., Borkin, M. S., Boyd, S. L., & Terlecky, S. R. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.122 · Cited by 205
“One particular skin pathology, psoriasis, is an incurable disorder that has been defined as a chronic inflammatory disease largely mediated by immune cells (Nickoloff and Nestle, 2004).”
BackgroundMolecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases
Tai, Y., Wang, Q., Korner, H., Zhang, L., & Wei, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00642 · Cited by 196
“LFA-3 Ig (Alefacept) and Anti-LFA-1 Antibody (Efalizumab) Inhibit CD2 Signaling in T Cells It had been demonstrated that an LFA-3 Ig fusion protein (Alefacept) could reduce psoriasis lesions (Nickoloff and Nestle, 2004).”
BackgroundTargeting leukocyte integrins in human diseases
Yonekawa, K., & Harlan, J. M. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804460 · Cited by 194
“Eventually, epidermal thickening, an angiogenic tissue reaction, and plaque formation result [164].”
BackgroundPradhan, M., Singh, D., & Singh, M. R. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.020 · Cited by 190
Sano, S., Chan, K. S., & DiGiovanni, J. (2008) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2007.05.016 · Cited by 182
“Over the last decade, researchers and clinicians have regarded T cells as the predominant contributors to this disease, with the development of models in immunodeficient mice in which psoriatic skin is grafted with and without T cells, and with the introduction of immune-directed therapies, including T cell-targeted i…”
BackgroundThe cytokine and chemokine network in psoriasis
Nickoloff, B. J., Xin, H., Nestle, F. O., & Qin, J.-Z. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2007.08.011 · Cited by 180
Self-citationPlikus, M. V., Van Spyk, E. N., Pham, K., Geyfman, M., Kumar, V., Takahashi, J. S., & Andersen, B. (2015) · Journal of Biological Rhythms · doi:10.1177/0748730414563537 · Cited by 175
“…deregulation of the cutaneous immune system is causally associated with many inflammatory skin diseases, prominently psoriasis (Schon et al., 1997; Nickoloff and Nestle, 2004) and atopic dermatitis (Leung et al., 2004; De Benedetto et al., 2009), emphasizing the importance of balancing the immune…”
National Psoriasis Foundation Clinical Consensus on Disease Severity
Pariser, D. M., Bagel, J., Gelfand, J. M., Korman, N. J., Ritchlin, C. T., Strober, B. E., Van Voorhees, A. S., Young, M., Rittenberg, S., Lebwohl, M. G., et al. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.2.239 · Cited by 175
Innate immunity and antimicrobial defense systems in psoriasis
Büchau, A. S., & Gallo, R. L. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2007.08.016 · Cited by 169
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
Skvara, H., Dawid, M., Kleyn, E., Wolff, B., Meingassner, J. G., Knight, H., Dumortier, T., Kopp, T., Fallahi, N., Stary, G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35636 · Cited by 163
Genetic and epigenetic basis of psoriasis pathogenesis
Chandra, A., Ray, A., Senapati, S., & Chatterjee, R. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.12.014 · Cited by 161
“A plausible echanistic hypothesis about the pathogenesis of psoriasis sug- ests abnormal activation and migration of T-cells into the skin and ventual aggregation of inflammatory cells, followed by psoriaticlaque development, mediated by CD4+ and CD8+ T-cells (Gervin t al., 2012; Lowes et al., 2013; Nickoloff and Nest…”
BackgroundInfluentialLehmann, J. C. U., Listopad, J. J., Rentzsch, C. U., Igney, F. H., von Bonin, A., Hennekes, H. H., Asadullah, K., & Docke, W.-D. F. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700686 · Cited by 158
“cells and their proinflammatory type 1 cytokine production pattern in the pathophysiology of psoriasis (Asadullah et al., 2002; Nickoloff and Nestle, 2004), leading to the assumption that the antipsoriatic activity of FAE is mediated by immune deviation.”
BackgroundCorticotropin releasing hormone and the skin
Slominski, A. (2006) · Frontiers in bioscience · doi:10.2741/1966 · Cited by 157
Polat, B. E., Blankschtein, D., & Langer, R. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.538679 · Cited by 164
“This may be particularly relevant to skin disorders where the delivery of active therapeutics through the skin represents a limiting transport step, and the number of side effects can be limited by localized therapy, such as in the case of psoriasis plaques [80,81].”
BackgroundMannan induces ROS-regulated, IL-17A–dependent psoriasis arthritis-like disease in mice
Khmaladze, I., Kelkka, T., Guerard, S., Wing, K., Pizzolla, A., Saxena, A., Lundqvist, K., Holmdahl, M., Nandakumar, K. S., & Holmdahl, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405798111 · Cited by 150
“Ps is a skin disease having systemic manifestations (1).”
BackgroundThe pathogenic role of tissue-resident immune cells in psoriasis
Boyman, O., Conrad, C., Tonel, G., Gilliet, M., & Nestle, F. O. (2007) · Trends in Immunology · doi:10.1016/j.it.2006.12.005 · Cited by 151
Self-citationTargeting chemokine receptors in chronic inflammatory diseases: An extensive review
Koelink, P. J., Overbeek, S. A., Braber, S., de Kruijf, P., Folkerts, G., Smit, M. J., & Kraneveld, A. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.008 · Cited by 169
Diluvio, L., Vollmer, S., Besgen, P., Ellwart, J. W., Chimenti, S., & Prinz, J. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.7104 · Cited by 157
“According to current concepts, psoriasis represents a T cell-mediated autoimmune disease (11, 14, 34).”
BackgroundSmith, C. H., & Barker, J. N. (2006) · BMJ · doi:10.1136/bmj.333.7564.380 · Cited by 141
Psoriasis and metabolic syndrome
Takahashi, H., & Iizuka, H. (2011) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2011.01408.x · Cited by 162
Epigenetics in human autoimmunity
Strickland, F. M., & Richardson, B. C. (2008) · Autoimmunity · doi:10.1080/08916930802024616 · Cited by 142
“Psoriasis occurs equally in men and women, and exhibits enhanced keratinocyte proliferation caused by exuberant inflammatory infiltrates into the epidermis and dermis [58].”
BackgroundEpidermal Differentiation in Barrier Maintenance and Wound Healing
Wikramanayake, T. C., Stojadinović, O., & Tomic‐Canic, M. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0503 · Cited by 149
“Patients may also develop inflammatory bowel disorder.(36) Although several psoriasis susceptibility loci have been identified, no specific gene has been validated as a definite cause for psoriasis.”
BackgroundImmune privilege in sites of chronic infection: Leishmania and regulatory T cells
Peters, N., & Sacks, D. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00432.x · Cited by 132
“Although the pathogenesis of psoriasis is not fully understood, clinical disease is likelymediated by self-specific effector T cells, which sustain a cycle of cytokine, chemokine, and growth factor production in a skin lesion that can resolve spontaneously (202).”
BackgroundConnexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response
Djalilian, A. R., McGaughey, D. M., Patel, S., Seo, E. Y., Yang, C., Cheng, J., Tomić, M., Sinha, S., Ishida‐Yamamoto, A., & Segre, J. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27186 · Cited by 149
Reich, K., Nestle, F. O., Papp, K. A., Ortonne, J. ‐., Wu, Y., BALA, M. M., Evans, R., Guzzo, C. A., Li, S., Dooley, L. T., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07237.x · Cited by 138
Self-citationImpaired Langerhans cell migration in psoriasis
Cumberbatch, M., Singh, M., Dearman, R. J., Young, H. S., Kimber, I., & Griffiths, C. E. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052367 · Cited by 127
“Nevertheless, such a dramatic functional diff erence as that described here has not previously been identifi ed within nonlesional skin, and the expectation has been that the skin of susceptible subjects would, if anything, be associated with enhanced traffi c of LCs and other leukocytes (35).”
BackgroundMrowietz, U., Elder, J. T., & Barker, J. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-006-0707-8 · Cited by 125
“cells are found in the dermis and epidermis and are accompanied by increased numbers of dermal dendritic cells, macrophages and mast cells [51].”
BackgroundDysregulation of T-Cell Function in the Elderly: Scientific Basis and Clinical Implications
Fülöp, T., Larbi, A., Wikby, A., Mocchegiani, E., Hirokawa, K., & Pawelec, G. (2005) · Drugs & Aging · doi:10.2165/00002512-200522070-00005 · Cited by 131
Interplay between keratinocytes and immune cells—Recent insights into psoriasis pathogenesis
Tonel, G., & Conrad, C. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.10.022 · Cited by 140
Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease
Ouyang, W. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.10.007 · Cited by 126
“In the pathogenesis of psoriasis, many other cytokines are also upregulated [48,49].”
BackgroundInfluentialInflammation and Cancer: Is the Link as Simple as We Think?
Nickoloff, B. J., Ben-Neriah, Y., & Pikarsky, E. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23724.x · Cited by 110
“Moreover, conversion from clinically symptomless skin to thick, erythematous scaling plaques includes a remodeling of both epidermal and dermal compartments with neovascularization accompanied by activation of CD4þ T cells and other immunocytes (Nickoloff and Nestle, 2004).”
BackgroundSelf-citationTovar‐Castillo, L. E., Cancino‐Díaz, J. C., García-Vázquez, F., Cancino‐Gómez, F. G., León‐Dorantes, G., Blancas‐González, F., Jiménez-Zamudio, L. A., García-Latorre, E., & Cancino-Diaz, M. E. (2006) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2006.02962.x · Cited by 111
Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease
Ghazizadeh, R., Shimizu, H., Tosa, M., & Ghazizadeh, M. (2010) · International Journal of Medical Sciences · doi:10.7150/ijms.7.284 · Cited by 126
“Histologically, psoriasis and atherosclerosis show common features of infiltrating T-cells, monocytes/macrophages, neutrophils, dendritic cells (DCs) and mast cells [28, 29].”
BackgroundWang, C., Wu, L., Bulek, K., Martin, B. N., Zepp, J. A., Kang, Z., Liu, C., Herjan, T., Misra, S., Carman, J. A., et al. (2013) · Nature Immunology · doi:10.1038/ni.2479 · Cited by 107
“T cells restored with the D10N variant, but not the wild-type Act1, showed a hyper T H 17 phenotype, demonstrating that the nonfunctional Act1 is associated with a dysregulation of T cell function, a risk factor for autoimmune diseases including psoriasis 1, 2, 41 .”
BackgroundTse, W.-P., Che, C., Liu, K., & Lin, Z. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.04.023 · Cited by 104
The Relapse of Psoriasis: Mechanisms and Mysteries
Tian, D., & Lai, Y. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100116 · Cited by 118
“Several theories and models have been proposed to elaborate this immunopathology of psoriasis (Nestle et al., 2009; Nickoloff and Nestle, 2004).”
BackgroundCai, L., Gu, J., Zheng, J., Zheng, M., Wang, G., Xi, L., Hao, F., Liu, X. ‐., Sun, Q. ‐., Wang, Y., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13746 · Cited by 102
Williams, F., Meenagh, A., Sleator, C., Cook, D., Fernández-Viña, M., Bowcock, A. M., & Middleton, D. (2005) · Human Immunology · doi:10.1016/j.humimm.2005.04.005 · Cited by 110
Vijayalakshmi, A., Ravichandiran, V., Velraj, M., Nirmala, S., & Jayakumari, S. (2012) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(12)60021-5 · Cited by 99
“It affects the patients physically, mentally and socially[1,2].”
BackgroundWolf, P., Nghiem, D. X., Walterscheid, J. P., Byrne, S. N., Matsumura, Y., Matsumura, Y., Bucana, C., Ananthaswamy, H. N., & Ullrich, S. E. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060079 · Cited by 100
“This goes well in line with the clinical knowledge that suberythemal PUVA exposure is beneficial for psoriasis but exposure to PUVA above the phototoxicity dose can lead to aggravation of the disease by a process called koebnerization.(32) The finding that PAF pathway blockade (Figure 3) does reduce PUVA-induced apopt…”
BackgroundA comprehensive review of biomarkers in psoriasis
Rashmi, R., Rao, K. S. J., & Basavaraj, K. H. (2009) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2009.03410.x · Cited by 114
Suárez‐Fariñas, M., Arbeit, R. D., Jiang, W., Ortenzio, F. S., Sullivan, T., & Krueger, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084634 · Cited by 98
“Psoriasis is a chronic inflammatory disease of the skin, characterized by keratinocyte hyperplasia, dermal leukocyte infiltration and dermal vascular enhancement [1].”
BackgroundSHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis
Ruchusatsawat, K., Wongpiyabovorn, J., Shuangshoti, S., Hirankarn, N., & Mutirangura, A. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0020-6 · Cited by 99
“quence of autoimmune reaction [15].”
Madanagobalane, S., & Anandan, S. (2012) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2012.00905.x · Cited by 95
“Psoriasis is a chronic, immunologically mediated inflammatory skin disease.(1) Over the last decade many studies world over have shown that people with psoriasis often have comorbidities like diabetes, hypertension and lipid abnormalities.”
BackgroundReview Paper: Preclinical Models of Psoriasis
Danilenko, D. M. (2008) · Veterinary Pathology · doi:10.1354/vp.45-4-563 · Cited by 106
Fujimura, T., Okuyama, R., Ito, Y., & Aiba, S. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08504.x · Cited by 93
de Koning, H. D., van den Bogaard, E. H., Bergboer, J. G. M., Kamsteeg, M., van Vlijmen-Willems, I. M. J. J., Hitomi, K., Henry, J., Simon, M., Takashita, N., Ishida-Yamamoto, A., et al. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10885.x · Cited by 90
Cathelicidin LL‐37: a defense molecule with a potential role in psoriasis pathogenesis
Dombrowski, Y., & Schauber, J. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01459.x · Cited by 97
Channual, J. C., Wu, J. J., & Dann, F. J. (2009) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2008.01217.x · Cited by 93
Jiang, W., Zhu, F., Bhagat, L., Yu, D. S., Tang, J. X., Kandimalla, E. R., Monica, N. L., & Agrawal, S. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.57 · Cited by 89
“INTRODUCTION Psoriasis is a chronic inflammatory skin disease characterized by hyperplasia of the epidermis, infiltration of leukocytes in dermis and epidermis, and dilation and growth of blood vessels (Nickoloff and Nestle, 2004).”
BackgroundHashim, I. A., Abo El-Magd, N. F., El‐Sheakh, A. R., Hamed, M. F., & El-Gawad, A. E.-G. H. A. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s156412 · Cited by 97
“Hence, such a disease influences the patients psychologically, physically, socially, and financially.(5,6) Clinically, the psoriatic disease is discriminated by sharply demarcated erythematous papules, as well as rounded plaques with silvery-white scales spread correspondence: Irhan Ibrahim abu hashim Department of Ph…”
BackgroundInhibition of JNK Promotes Differentiation of Epidermal Keratinocytes
Gazel, A., Banno, T., Walsh, R., & Blumenberg, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602712200 · Cited by 95
Recent Approaches for the Topical Treatment of Psoriasis Using Nanoparticles
Bodnár, K., Fehér, P. S., Ujhelyi, Z., Bácskay, I., & Józsa, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040449 · Cited by 112
Lin, Y., Yang, S., Chen, C., Kao, H.-C., & Fang, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137890 · Cited by 95
“Psoriasis is a chronic inflammatory skin disease characterized with epidermal hyperplasis, leukocyte infiltration, inflammation, and increased vascularity in dermis [1].”
BackgroundThe long-term efficacy and safety of new biological therapies for psoriasis
Papp, K. A. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-006-0660-6 · Cited by 82
“Psoriasis is a chronic inflammatory, immune-mediated disease characterized by periods of spontaneous remission and relapse [22].”
BackgroundYeilding, N. M., Szapary, P. O., Brodmerkel, C. M., Benson, J., Plotnick, M. I., Zhou, H., Goyal, K., Schenkel, B., Giles-Komar, J. M., Mascelli, M. A., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05963.x · Cited by 86
Pariser, D. M., Leonardi, C. L., Gordon, K. B., Gottlieb, A. B., Tyring, S. K., Papp, K. A., Li, J., & Baumgartner, S. W. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.07.040 · Cited by 81
CXCR2 ligands and G-CSF mediate PKC -induced intraepidermal inflammation
Cataisson, C., Pearson, A. J., Tsien, M. Z., Mascia, F., Gao, J., Pastore, S., & Yuspa, S. H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27514 · Cited by 84
Madanagobalane, S., & Anandan, S. (2012) · Indian Journal of Dermatology · doi:10.4103/0019-5154.100474 · Cited by 92
“There was no obvious difference in the other components of the MS between both the groups [Table 1].”
Arbiser, J. L., Govindarajan, B., Battle, T. E., Lynch, R. A., Frank, D. A., Ushio‐Fukai, M., Perry, B. N., Stern, D. F., Bowden, G. T., Liu, A., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700276 · Cited by 78
“Severe psoriasis is often treated with systemic medications, including methotrexate, cyclosporine, and retinoids, and more recently with biological agents, such as soluble receptors to tumor necrosis factoralpha (TNFa), or antibodies to TNFa receptors (Nickoloff and Wrone-Smith, 1999; Saurat, 1999; Oh et al., 2000; Go…”
BackgroundNickoloff, B. J., Bonish, B. K., Marble, D. J., Schriedel, K. A., DiPietro, L. A., Gordon, K. B., & Lingen, M. W. (2006) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650010 · Cited by 84
“This multicellular conspiracy generates a ‘‘perfect cytokine storm’’ that complements the cellular infiltrate, and joins together a confederacy of both soluble mediators and cellular constituents, manifesting itself from head to toe in genetically susceptible individuals as red thick scaly plaques (Uyemura et al., 199…”
BackgroundSelf-citationShawahna, R., & Jaradat, N. A. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1503-4 · Cited by 75
“Background Psoriasis is a frequent skin inflammatory disorder that inflicts approximately 2–3% of the populations around the globe [1, 2].”
BackgroundPsoriasis and uveitis: a literature review
Fraga, N. A. D. A., de Oliveira, M. D. F. P., Follador, I., Rocha, B. D. O., & Rêgo, V. R. P. D. A. (2012) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962012000600009 · Cited by 74
Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper
Girolomoni, G., Griffiths, C. E. M., Krueger, J. G., Nestle, F. O., Nicolas, J., Prinz, J. C., Puig, L., Ståhle, M., van de Kerkhof, P. C. M., Allez, M., et al. (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2014.880396 · Cited by 78
“macrophages, and neutrophils), the production of collagen and proteoglycans by fibroblasts, the activation and perpetuation of an inflammatory response, and the propagation of an adaptive immune response (11,65).”
Self-citationThe role of dendritic cells in the immunopathogenesis of psoriasis
Jariwala, S. P. (2007) · Archives of Dermatological Research · doi:10.1007/s00403-007-0775-4 · Cited by 80
“Along these lines, the AGR129 mouse xenograft model has suggested that the localized expansion of T-cells along with downstream cytokine production play important roles in the development of psoriatic plaques [7, 51 ].”
BackgroundInfluential
Metadata
- Authors
- Nickoloff, B. J., & Nestle, F. O.
- Affiliations
- Loyola University Medical Center (US)
- University of Zurich (CH)
- Corresponding author
- Nickoloff, Brian J.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-06-15
- Volume
- 113
- Issue
- 12
- Pages
- 1664-1675
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC420513
- OpenAlex
- W2024387258
- Cited by
- 544
- References
- 110
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 18 · 2020: 10 · 2019: 23 · 2018: 18 · 2017: 17 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 29 · 2012: 27
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR40065, R01AR040065)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, immunopathogenesis, T cells, immunological synapse, cytokine signaling pathways, xenotransplantation model, targeted therapy, psoriasis genetics, chronic skin inflammation, psoriatic arthritis
- MeSH terms
- Animals, Dermatologic Agents, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Psoriasis, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.